Incoming BIO CEO Michelle McMurry-Heath (BIO)
May 14, 2020 09:41 AM EDTUpdated 09:51 AM
People
Bioregnum
Opinion

BIO gets a new chief lob­by­ist to face off against the grow­ing ranks of crit­ics in Con­gress

BIO has se­lect­ed its next CEO to suc­ceed James Green­wood as one of biotech’s top lob­by­ists. And she comes with a dream ré­sumé that rings …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Why Re­gen­eron is buy­ing 23andMe

David Liu, Sam Stern­berg un­veil new way to in­sert big genes in hu­man cells

Re­gen­eron plans to buy 23andMe for $256M

In­tel­li­a's CRISPR ther­a­py like­ly caus­es 'per­ma­nen­t' gene knock­down in AT­TR amy­loi­do­sis

Boehringer In­gel­heim’s late-stage da­ta for lung dis­ease can­di­date un­der­whelm some an­a­lysts

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times